Benzodiazepines (systemic clonazepam) vs placebo
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
- Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · systemic clonazepamMD -0.20 [-0.95, 0.55]1 study · 20 participantsVery low